The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42.
Loss of expression of the TGF-beta superfamily coreceptor, the type III TGF-beta receptor (TbetaRIII or betaglycan), occurs in a broad spectrum of human cancers including breast, lung, ovarian, pancreatic, prostate, and renal cell cancer. TbetaRIII suppresses cancer progression in vivo, at least in part, by reducing cancer cell motility. However, the mechanism by which TbetaRIII regulates migration is unknown. Here, we demonstrate an unexpected TGF-beta signaling independent role for TbetaRIII in activating Cdc42, altering the actin cytoskeleton and reducing directional persistence to inhibit random migration of both cancer and normal epithelial cells. Functionally, TbetaRIII through its interaction with the scaffolding protein beta-arrestin2, activates Cdc42 and inhibits migration. These studies identify a TGF-beta independent homeostatic function for TbetaRIII in regulating cell migration.
Mythreye
Karthikeyan
K
Department of Medicine and Pharmacology, Duke University Medical Center, Durham, NC 27708, USA.
Blobe
Gerard C
GC
D000199:Actins; D019390:Arrestins / Q000378:metabolism*; D045744:Cell Line, Tumor; D002465:Cell Movement; D003599:Cytoskeleton; D004847:Epithelial Cells / Q000502:physiology*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000473:pathology*; D011509:Proteoglycans / Q000502:physiology*; D018125:Receptors, Transforming Growth Factor beta / Q000502:physiology*; D000071557:beta-Arrestins; D020764:cdc42 GTP-Binding Protein / Q000378:metabolism*
D000199:Actins; D019390:Arrestins; D011509:Proteoglycans; D018125:Receptors, Transforming Growth Factor beta; D000071557:beta-Arrestins; C071736:betaglycan; D020764:cdc42 GTP-Binding Protein